Overview

Development of NIC5-15 in the Treatment of Alzheimer's Disease

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Collaborators:
Humanetics Corporation
National Center for Complementary and Integrative Health (NCCIH)